 |
| Relapsed or Refractory Diffuse Large B-cell Lymphoma Market |
The relapsed or refractory diffuse large B-cell lymphoma market has witnessed significant growth over the past few years owing to the increasing prevalence of lymphoma across the globe. Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that affects B-cells and accounts for around 30% of newly diagnosed cases of non-Hodgkin lymphoma. Despite advances in upfront treatment options like combination chemoimmunotherapy, up to 40% of patients experience relapse or become refractory. Treatment of relapsed/refractory DLBCL aims to control tumor growth, reduce symptoms, improve quality of life, and potentially cure the disease. The key therapies for relapsed and refractory DLBCL include CAR T-cell therapy, monoclonal antibodies, and chemotherapy. The Global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1777.75 Bn in 2024 and is expected to exhibit a CAGR of 16.% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the relapsed or refractory diffuse large B-cell
lymphoma are Sharp Corp., LG, Samsung, Hitachi, and Panasonic. These key
players are focusing on developing innovative and better treatment options for
relapsed/refractory DLBCL patients. For instance, in 2021, LG Corporation
launched a chimeric antigen receptor T-cell therapy drug for the treatment of
relapsed/refractory DLBCL.
There is significant opportunity in the market related to the development of
combination therapies. The combination of CAR T-cell therapy, monoclonal
antibodies and other therapies is expected to provide better outcomes for
relapsed/refractory patients. For example, the combination of anti-CD19 CAR
T-cell therapy with monoclonal antibodies like rituximab or obinutuzumab.
The major players are expanding globally to increase their market share in the
high growth regional markets. For instance, in 2022, Hitachi expanded its
operations in Latin America by acquiring a Brazilian medical device company to
strengthen its position in the relapsed/refractory oncology market.
Market drivers
The increasing prevalence of lymphoma is a major driver of the Relapsed
Or Refractory Diffuse Large B-Cell Lymphoma Market Trends According to the estimates of Lymphoma
Research Foundation, around 74,200 people will be diagnosed with some form of
non-Hodgkin lymphoma in 2021 in the US. Further, technological advancements
leading to development of novel targeted therapies like CAR T-cell therapy and
monoclonal antibodies are expected to drive the market growth during the
forecast period.
Market restraints
High cost of the targeted therapies like CAR T-cell therapy remains one of the
major challenges in the market. The total cost of CAR T-cell therapy can range
from $250,000 to $400,000 per patient in the US. Further, complex manufacturing
process of cell and gene therapy products also adds to their overall cost. This
high cost restrains the adoption of these novel therapies, especially in low
and middle-income countries.
Segment Analysis
The relapsed or refractory diffuse large B-cell lymphoma market can be
segmented based on treatment type and geography. Based on treatment type, the
market can be classified into monoclonal antibodies, chemotherapy, targeted
therapy, and others. Among these, the monoclonal antibodies segment dominated
the market in 2024 owing to the increased adoption of antibodies like Rituximab
and Brentuximab for treating relapsed/refractory DLBCL. Monoclonal antibodies
provide durable long-term benefits to patients and have better survival
outcomes than conventional chemotherapy treatments.
Global Analysis
Regionally, North America dominated the relapsed or refractory diffuse large
B-cell lymphoma market in 2024 and is expected to continue its dominance during
the forecast period. This is owing to the developed healthcare infrastructure,
high treatment cost, and presence of key players in the region. However, Asia
Pacific is anticipated to witness the highest growth rate during 2024-2030 due
to large patient population, increasing incidence of lymphoma, rising
healthcare expenditure, and improving healthcare facilities in emerging
countries such as China and India. The key players globally are focusing on
launching innovative treatment therapies and undertaking partnerships and
agreements to strengthen their market position and expand presence across
different regions.
0 Comments